Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt unloaded 7,014 shares of United Therapeutics stock on the open market in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $92.46, for a total value of $648,514.44. Following the sale, the chief executive officer now directly owns 140 shares in the company, valued at approximately $12,944. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

UTHR has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of United Therapeutics from $133.00 to $141.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Standpoint Research raised their price target on shares of United Therapeutics from $118.00 to $140.00 in a research note on Friday. They now have a “buy” rating on the stock. Finally, analysts at Zacks upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Thursday, August 21st. They now have a $112.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $104.87.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 28.51% on Friday, hitting $117.83. 6,441,510 shares of the company’s stock traded hands. United Therapeutics has a 52-week low of $70.68 and a 52-week high of $116.65. The stock has a 50-day moving average of $91.63 and a 200-day moving average of $95.41. The company has a market cap of $5.570 billion and a P/E ratio of 17.72.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter last year, the company posted $1.52 earnings per share. United Therapeutics’s revenue was up 15.0% compared to the same quarter last year. Analysts expect that United Therapeutics will post $8.55 EPS for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Receive News & Ratings for United Therapeutics Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co and related companies with Analyst Ratings Network's FREE daily email newsletter.